Tackling Tablet Sticking - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Tackling Tablet Sticking
Rob Blanchard and Clive Roberts discuss the issues surrounding tablet sticking and the collaboration of I Holland with Nottingham University to improve tabletting science, which was announced in March 2012

Pharmaceutical Technology Europe


Q: What techniques are necessary to further examine the intricacies of tablet sticking? How will the results of these techniques be combined to increase knowledge?

The project is exploiting a range of advanced surface analytical techniques to derive chemical and physical data from drug and excipients particles. The work also involves quantitatively mapping adhesion at the nano and micro scale using single drug particles, and links this adhesion data to actual tabletting experiments utilising a range of novel and controllable surface coated tablet punches with well‑defined characteristics. Multivariate analysis and principal component analysis will be used to identify the parameter(s) that influence sticking to form the basis of a model to predict propensity for sticking, based upon these factors. The ongoing use of the advanced techniques employed to collect the data in this research should not be required to implement this prediction in a commercial environment.

Q: Are there any particular areas that the collaboration will focus on?

Previous research has focused on only a few excipients and therefore did not allow a predictive tool to be developed that would allow selection of the correct coating without the need of expensive and time consuming compression trials. The aim of I Holland’s research and development team is to speed response times to solving customers’ problems, ultimately offering better customer service.


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
How does your company apply quality-by-design (QbD) principles to manufacturing processes?
To all processes for both new and legacy products
To all process for new products only
To select process for new products only
To select processes for both new and legacy products
Do not use QbD
To all processes for both new and legacy products
18%
To all process for new products only
13%
To select process for new products only
22%
To select processes for both new and legacy products
22%
Do not use QbD
24%
View Results
UPCOMING CONFERENCES

Programs for Investigational and Pre-Launch Drugs
Philadelphia, PA
July 17-18, 2013
Request Brochure

Strategic Pipeline Planning & Portfolio Valuation
Philadelphia, PA
August 13-14, 2013
Request Brochure

MES 2013 - Forum on Manufacturing Execution Systems
Philadelphia, PA
August 14-15, 2013
Request Brochure

Mobile Innovation for the Life Sciences Industry
Philadelphia, PA
August 20-21, 2013
Request Brochure

See All Conferences >>

Eric Langer Outsourcing Outlook Eric LangerOutsourcing's Modest Role as a Cost-Containment Strategy
Patricia Van Arnum Ingredients Insider Patricia Van ArnumIntellectual Property Battles in Solid-State Chemistry
Nathan Jessop Industry Insider Nathan Jessop Campaign Against Counterfeit Drugs Continues
Lynn Torbeck Statistical Solutions Lynn D. TorbeckCompositing Samples and the Risk to Product Quality
 More
Inadequate Access to Medicines Puts EU at Risk
FDA Offers Insight on QbD for Modified-Release Products
Global Biosimilars Market to Reach $2.445 Billion in 2013
Adapting to Change
AstraZeneca and Exco InTouch Collaborate to Augment Current COPD Pathways
FindPharma Custom Search
Source: Pharmaceutical Technology Europe,
Click here